The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection
- PMID: 3040815
- DOI: 10.1016/s0190-9622(87)70194-7
The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection
Abstract
Itraconazole in a new, orally active triazole, which is related to ketoconazole and which is active against dermatophytes and Candida and Cryptococcus organisms. It is more potent than ketoconazole, is better absorbed with food, and does not suppress testosterone or cortisol synthesis. In previous studies, daily 200 mg doses of itraconazole for 5 days cleared 80% of cases of pityriasis versicolor, and 90% of dermatophyte infections were cleared by daily 100 mg doses administered for 1 month. Twenty patients with superficial dermatophyte, Candida albicans, and pityriasis versicolor infections were treated with doses of 50 or 100 mg per day; in the first group of 10 patients, the drug was administered before breakfast and the other 10 patients were given their dose with breakfast. Itraconazole concentration was determined by high-performance liquid chromatography 3 hours after administration of first and last doses. Our findings showed that although treatment with 50-mg doses led to poorer results and lower plasma levels than 100-mg doses, taking the drug with breakfast gave much better results than taking it before.
Similar articles
-
Itraconazole in the treatment of superficial mycoses--a double-blind study vs. placebo.Clin Exp Dermatol. 1990 Mar;15(2):101-4. doi: 10.1111/j.1365-2230.1990.tb02041.x. Clin Exp Dermatol. 1990. PMID: 2161302 Clinical Trial.
-
Itraconazole in the treatment of superficial mycoses: an open trial of 40 cases.Rev Infect Dis. 1987 Jan-Feb;9 Suppl 1:S100-3. doi: 10.1093/clinids/9.supplement_1.s100. Rev Infect Dis. 1987. PMID: 3027831 Clinical Trial.
-
Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models.Rev Infect Dis. 1987 Jan-Feb;9 Suppl 1:S15-32. doi: 10.1093/clinids/9.supplement_1.s15. Rev Infect Dis. 1987. PMID: 3027843 Review.
-
Itraconazole in the treatment of human mycoses: review of three years of clinical experience.Rev Infect Dis. 1987 Jan-Feb;9 Suppl 1:S146-52. doi: 10.1093/clinids/9.supplement_1.s146. Rev Infect Dis. 1987. PMID: 3027842 Clinical Trial.
-
Itraconazole in common dermatophyte infections of the skin: fixed treatment schedules.J Am Acad Dermatol. 1990 Sep;23(3 Pt 2):554-8. doi: 10.1016/0190-9622(90)70253-e. J Am Acad Dermatol. 1990. PMID: 2170473 Review.
Cited by
-
Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.Drugs. 1992 Jul;44(1):9-35. doi: 10.2165/00003495-199244010-00002. Drugs. 1992. PMID: 1379913 Review.
-
Pharmacology of itraconazole.Drugs. 2001;61 Suppl 1:27-37. doi: 10.2165/00003495-200161001-00003. Drugs. 2001. PMID: 11219548 Review.
-
The Impact of Dietary Interventions on the Pharmacokinetics of Antifungal Drugs: A Systematic Review with Meta-analyses.Clin Pharmacokinet. 2025 Jun;64(6):815-848. doi: 10.1007/s40262-025-01511-6. Epub 2025 May 10. Clin Pharmacokinet. 2025. PMID: 40347349
-
Effect of cyclodextrin on the pharmacology of antifungal oral azoles.Antimicrob Agents Chemother. 1992 Feb;36(2):477-80. doi: 10.1128/AAC.36.2.477. Antimicrob Agents Chemother. 1992. PMID: 1605615 Free PMC article.
-
Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.Antimicrob Agents Chemother. 1993 Dec;37(12):2762-5. doi: 10.1128/AAC.37.12.2762. Antimicrob Agents Chemother. 1993. PMID: 8109952 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources